STTR Phase I: A therapeutic molecule for COVID-19

这个小型企业技术转让(STTR)第一阶段项目的更广泛影响是为冠状病毒大流行提供治疗解决方案。冠状病毒与几次疫情有关，包括之前的SARS和MERS。拟议的治疗方法将抑制病毒的复制能力，并诱导人体免疫系统杀死病毒。此外，这项研究还可以应用于其他病毒的解决方案，包括RSV、乙肝和艾滋病毒/艾滋病。该项目将提出一种集成疫苗、小分子抑制剂和抗体的方法。该项目将识别一种以病毒为靶标并与其结合的小分子，然后将其与向人体免疫系统发出信号的小有效载荷联系起来。该项目将确定和开发一种能够有效结合多种冠状病毒毒株的靶向分子和促进适当免疫反应的有效载荷。该奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact of this Small Business Technology Transfer (STTR) Phase I project is to provide a therapeutic solution for coronavirus pandemics. Coronaviruses have been implicated in several outbreaks, including prior SARS and MERS. The proposed therapeutic will inhibit the virus’s ability to replicate and elicit the body's immune system to kill the virus. In addition, this research can be applied to solutions for other viruses including RSV, hepatitis B and HIV/AIDS.The proposed project will advance a method integrating vaccines, small molecule inhibitors, and antibodies. This project will identify a small molecule that targets and binds to the virus, then link it to a small payload that signals the body's immune system. This project will identify and develop a targeting molecule that can bind effectively to multiple strains of the coronavirus and a payload that promotes an appropriate immune response.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.